Manisagar Bio Sciences Profile
Key Indicators
- Authorised Capital ₹ 0.20 M
- Paid Up Capital ₹ 0.20 M
- Company Age 7 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 7.00 M
- Revenue Growth 54.40%
- Profit Growth -71.87%
- Ebitda 14.43%
- Net Worth 14.33%
- Total Assets 60.51%
About Manisagar Bio Sciences
Manisagar Bio Sciences Private Limited (MBSPL) is a Private Limited Indian Non-Government Company incorporated in India on 03 February 2017 (Seven years and 11 months 26 days old ). Its registered office is in Sabarkantha, Gujarat, India.
The Company is engaged in the Agriculture Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.20 M and a paid-up capital of Rs 0.20 M.
The company currently has active open charges totaling ₹7.00 M.
Pawan Mishra, Govind Nagar, and Nirmal Mehta serve as directors at the Company.
Company Details
- Location
Sabarkantha, Gujarat, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media-
Corporate Identity Details
- CIN/LLPIN
U01100GJ2017PTC095375
- Company No.
095375
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Feb 2017
- Date of AGM
20 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Who are the key members and board of directors at Manisagar Bio Sciences?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nirmal Mehta  | Director | 04-Feb-2022 | Current |
| Pawan Mishra | Director | 03-Sep-2020 | Current |
| Govind Nagar | Director | 18-Feb-2019 | Current |
Financial Performance of Manisagar Bio Sciences.
Manisagar Bio Sciences Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 54.4% increase. The company also saw a substantial fall in profitability, with a 71.87% decrease in profit. The company's net worth Soared by an impressive increase of 14.33%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Manisagar Bio Sciences?
In 2021, Manisagar Bio Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹7.00 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.70 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 28 Jul 2020 | Others | ₹4.00 M | Open |
| 21 May 2020 | Others | ₹3.00 M | Open |
How Many Employees Work at Manisagar Bio Sciences?
Unlock and access historical data on people associated with Manisagar Bio Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Manisagar Bio Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Manisagar Bio Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
